Reviva to Participate in the 4th Annual Roth Healthcare Opportunities Conference
Reviva Pharmaceuticals (NASDAQ: RVPH), a late-stage pharmaceutical company focused on CNS, inflammatory and cardiometabolic diseases, announced its participation in the 4th Annual Roth Healthcare Opportunities Conference on October 9, 2025, in New York.
CEO Laxminarayan Bhat will join a panel discussion titled "Small Firms Tackling Blockbuster Indications" at 8:00 AM ET and will be available for one-on-one meetings with investors throughout the day.
Reviva Pharmaceuticals (NASDAQ: RVPH), azienda farmaceutica in fase avanzata focalizzata su malattie CNS, infiammatorie e cardiometaboliche, ha annunciato la sua partecipazione alla 4ª Conferenza annuale Roth Healthcare Opportunities il 9 ottobre 2025 a New York.
Il CEO Laxminarayan Bhat parteciperà a una tavola rotonda intitolata "Small Firms Tackling Blockbuster Indications" alle 8:00 AM ET e sarà disponibile per incontri one-to-one con gli investitori durante l'arco della giornata.
Reviva Pharmaceuticals (NASDAQ: RVPH), una empresa farmacéutica en fase avanzada centrada en enfermedades del SNC, inflamatorias y cardiometabólicas, anunció su participación en la 4th Annual Roth Healthcare Opportunities Conference el 9 de octubre de 2025 en Nueva York.
El CEO Laxminarayan Bhat participará en un panel titulado "Small Firms Tackling Blockbuster Indications" a las 8:00 AM ET y estará disponible para reuniones individuales con inversores a lo largo del día.
Reviva Pharmaceuticals (NASDAQ: RVPH)는 CNS, 염증 및 심대사 질환에 중점을 둔 후기단계 제약회사로, 2025년 10월 9일 뉴욕에서 열리는 제4회 Roth Healthcare Opportunities Conference에 참가를 발표했습니다.
CEO Laxminarayan Bhat은 오전 8시 ET에 진행되는 대형 신약 지표를 다루는 소규모 기업 패널 토론에 참여하며 하루 종일 투자자들과의 일대일 미팅이 가능합니다.
Reviva Pharmaceuticals (NASDAQ: RVPH), une société pharmaceutique en fin de développement axée sur les maladies du SNC, inflammatoires et cardiométaboliques, a annoncé sa participation à la 4th Annual Roth Healthcare Opportunities Conference le 9 octobre 2025 à New York.
Le PDG Laxminarayan Bhat participera à une table ronde intitulée "Small Firms Tackling Blockbuster Indications" à 8h00 HE et sera disponible pour des meetings en tête-à-tête avec les investisseurs tout au long de la journée.
Reviva Pharmaceuticals (NASDAQ: RVPH), ein in der späten Forschungs- und Entwicklungsphase befindliches Pharmaunternehmen mit Fokus auf CNS-, Entzündungs- und kardiometabolische Erkrankungen, kündigte seine Teilnahme an der 4th Annual Roth Healthcare Opportunities Conference am 9. Oktober 2025 in New York an.
CEO Laxminarayan Bhat wird an einer Podiumsdiskussion mit dem Titel "Small Firms Tackling Blockbuster Indications" um 8:00 Uhr ET teilnehmen und wird im Laufe des Tages für Einzelgespräche mit Investoren zur Verfügung stehen.
Reviva Pharmaceuticals (NASDAQ: RVPH)، شركة أدوية في المرحلة الأخيرة تركز على أمراض الجهاز العصبي المركزي والالتهابات وأمراض التمثيل الغذائي القلبي، أعلنت عن مشاركتها في المؤتمر السنوي الرابع لفرص رعاية Roth Healthcare Opportunities في 9 أكتوبر 2025 في نيويورك.
سيشارك الرئيس التنفيذي لاكسيمينارايان بهات في جلسة نقاش بعنوان "Small Firms Tackling Blockbuster Indications" في الساعة 8:00 صباحاً بتوقيت شرق الولايات المتحدة وسيكون متاحاً لعقد اجتماعات فردية مع المستثمرين طوال اليوم.
Reviva Pharmaceuticals (NASDAQ: RVPH)，一家专注于中枢神经系统、炎症和心代谢疾病的晚期制药公司，宣布将参加于2025年10月9日在纽约举行的第4届 Roth Healthcare Opportunities Conference。
首席执行官 Laxminarayan Bhat 将参加题为“Small Firms Tackling Blockbuster Indications”的圆桌讨论，时间为美东时间上午8点，并将在当天全天提供与投资者一对一会谈的机会。
- None.
- None.
CUPERTINO, Calif., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in panel discussion and host one-on-one investor meetings at the 4th Annual Roth Healthcare Opportunities Conference, being held on October 9, 2025, in New York, NY.
Roth Healthcare Opportunities Conference
Format: Panel discussion and one-on-one meetings
Panel Title: “Small Firms Tackling Blockbuster Indications”
Date: Thursday, October 9, 2025
Time: 8:00 AM ET
To learn more and submit a registration request, click here. Reviva’s management team will be available for one-on-one investor meetings on October 9, 2025.
About Reviva
Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva’s current pipeline focuses on the central nervous system (CNS), inflammatory and cardiometabolic diseases. Reviva’s pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries.
Corporate Contact:
Reviva Pharmaceuticals Holdings, Inc.
Laxminarayan Bhat, PhD
www.revivapharma.com
Investor Relations Contact:
LifeSci Advisors, LLC
PJ Kelleher
pkelleher@lifesciadvisors.com
FAQ
When is Reviva Pharmaceuticals (RVPH) presenting at the Roth Healthcare Conference 2025?
What panel will RVPH's CEO participate in at the Roth Conference?
Will RVPH management be available for investor meetings at the Roth Conference?
What therapeutic areas does Reviva Pharmaceuticals focus on?
